Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Purchases of Investments
Cash used to buy marketable securities and other investments.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Purchases of Investments · Q4 FY2024 · quarter ended Dec 2024
Purchases of investments declines year over year
Q4 FY2024 purchases of investments of $11.36M (cash outflow) fell 43.3% year over year. Over 3 fiscal years it compounded at +6.5% a year.
Context
- Purchases of investments amounted to 199.0% of revenue in FY2025, down 234.3 pp from a year earlier.
- Purchases of investments grew in size in 2 of the last 3 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- (19.42M) USD
- Year-over-year change
- +45.2%
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (19.42M) | +45.2% |
| FY2024 | 2024-12-31 | (35.47M) | -91.3% |
| FY2023 | 2023-12-31 | (18.54M) | -15.3% |
| FY2022 | 2022-12-31 | (16.09M) | — |
| FY2021 | 2021-12-31 | 0 | — |
Purchases of Investments vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -45.2% is the 5th highest of 6, against a peer median of +27.3%.
- Purchases of investments amounts to 199.0% of revenue for NNNN, versus a peer median of 1.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $187M USD | -0.5% | -10.4% | 0.9% | |
| LTM Mar 2026 | $155.76M USD | +217.1% | +74.5% | 52.0% | |
| LTM Mar 2026 | $151.09M USD | -70.4% | -1.6% | 272.1% | |
| LTM Mar 2026 | $63M USD | +504.1% | — | 26.4% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $19.42M USD | -45.2% | +6.5% | 199.0% |
| LTM Dec 2025 | $15.42M USD | — | — | 13.3% | |
| LTM Mar 2026 | CA$11.45M CAD | +27.3% | -39.9% | 1.2% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Feb 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding NNNN) | — | +27.3% | -6.0% | 1.2% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.54M | 10.01M | 2.25M | 2.37M | 6.4M |
| Depreciation & Amortization | 0 | 6.25K | 12.06K | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.65M | (5.53M) | (1.2M) | 44.65K | (13.21M) |
| Accounts Receivables | (717.5K) | 717.5K | (1.88M) | 820.17K | (2.59M) |
| Inventory | 0 | (353.87K) | 353.87K | 0 | 0 |
| Accounts Payables | 1.89M | (481.82K) | (580.89K) | 798.1K | (1.63M) |
| Other Working Capital | 473.15K | (5.41M) | 907.97K | (1.57M) | (8.99M) |
| Other Non-Cash Items | 1 | (40.87K) | (163.39K) | (337.1K) | 68K |
| Operating Cash Flow | 4.18M | 4.45M | 898.37K | 2.08M | (6.74M) |
| Capital Expenditures | 0 | (3) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (16.09M) | (18.54M) | (35.47M) | (19.42M) |
| Sales of Investments | 0 | 14.56M | 20.27M | 35.8M | 15.22M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (1.53M) | 1.73M | 337.1K | (4.2M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 7.23M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (42.84K) | (344.61K) | (282.55K) |
| Financing Cash Flow | 0 | 0 | (42.84K) | (344.61K) | 6.95M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 4.18M | 2.92M | 2.59M | 2.07M | (3.99M) |
| Free Cash Flow | 4.18M | 4.45M | 898.37K | 2.08M | (6.74M) |
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.